Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1826 1
1946 1
1948 1
1950 1
1951 1
1952 3
1953 1
1954 2
1956 1
1960 1
1961 1
1962 1
1963 1
1964 1
1965 1
1966 2
1967 3
1968 4
1969 5
1970 4
1971 5
1972 8
1973 2
1974 9
1975 4
1976 6
1977 3
1978 6
1979 3
1980 5
1981 2
1982 4
1983 8
1984 5
1985 7
1986 7
1987 9
1988 15
1989 15
1990 21
1991 14
1992 18
1993 16
1994 18
1995 16
1996 18
1997 14
1998 37
1999 29
2000 34
2001 33
2002 47
2003 43
2004 44
2005 36
2006 45
2007 52
2008 70
2009 62
2010 68
2011 77
2012 97
2013 99
2014 109
2015 122
2016 156
2017 170
2018 183
2019 189
2020 177
2021 209
2022 201
2023 175
2024 133
2025 61

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,678 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for james bleed
Your search for James Bleeg retrieved no results
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, Lattimore S, Peerlinck K, Van der Valk P, Coppens M, Kampmann P, Meijer K, O'Connell N, Pasi KJ, Hart DP, Kazmi R, Astermark J, Hermans CRJR, Klamroth R, Lemons R, Visweshwar N, von Drygalski A, Young G, Crary SE, Escobar M, Gomez E, Kruse-Jarres R, Quon DV, Symington E, Wang M, Wheeler AP, Gut R, Liu YP, Dolmetsch RE, Cooper DL, Li Y, Goldstein B, Monahan PE. Pipe SW, et al. N Engl J Med. 2023 Feb 23;388(8):706-718. doi: 10.1056/NEJMoa2211644. N Engl J Med. 2023. PMID: 36812434 Clinical Trial.
BACKGROUND: Moderate-to-severe hemophilia B is treated with lifelong, continuous coagulation factor IX replacement to prevent bleeding. Gene therapy for hemophilia B aims to establish sustained factor IX activity, thereby protecting against bleeding without burdenso …
BACKGROUND: Moderate-to-severe hemophilia B is treated with lifelong, continuous coagulation factor IX replacement to prevent bleeding …
von Willebrand disease.
Seidizadeh O, Eikenboom JCJ, Denis CV, Flood VH, James P, Lenting PJ, Baronciani L, O'Donnell JS, Lillicrap D, Peyvandi F. Seidizadeh O, et al. Nat Rev Dis Primers. 2024 Jul 25;10(1):51. doi: 10.1038/s41572-024-00536-8. Nat Rev Dis Primers. 2024. PMID: 39054329 Review.
von Willebrand disease (VWD) is the most common inherited bleeding disorder. The disorder is characterized by excessive mucocutaneous bleeding. The most common bleeding manifestations of this condition include nosebleeds, bruising, bleeding from minor …
von Willebrand disease (VWD) is the most common inherited bleeding disorder. The disorder is characterized by excessive mucocutaneous …
Emergency Department Resuscitative Endovascular Balloon Occlusion of the Aorta in Trauma Patients With Exsanguinating Hemorrhage: The UK-REBOA Randomized Clinical Trial.
Jansen JO, Hudson J, Cochran C, MacLennan G, Lendrum R, Sadek S, Gillies K, Cotton S, Kennedy C, Boyers D, Ferry G, Lawrie L, Nath M, Wileman S, Forrest M, Brohi K, Harris T, Lecky F, Moran C, Morrison JJ, Norrie J, Paterson A, Tai N, Welch N, Campbell MK; UK-REBOA Study Group; Aylwin C, Bew D, Brooks A, Chinery J, Cowlam T, Frith D, George A, Hudson A, Johnstone P, Mahmood A, Novak A, O'Meara M, Reid S, Sattout A, Smith C, Stansfield T, Thompson J. Jansen JO, et al. JAMA. 2023 Nov 21;330(19):1862-1871. doi: 10.1001/jama.2023.20850. JAMA. 2023. PMID: 37824132 Free PMC article.
IMPORTANCE: Bleeding is the most common cause of preventable death after trauma. OBJECTIVE: To determine the effectiveness of resuscitative endovascular balloon occlusion of the aorta (REBOA) when used in the emergency department along with standard care vs standard care a …
IMPORTANCE: Bleeding is the most common cause of preventable death after trauma. OBJECTIVE: To determine the effectiveness of resusci …
Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.
Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Urban P, et al. Circulation. 2019 Jul 16;140(3):240-261. doi: 10.1161/CIRCULATIONAHA.119.040167. Epub 2019 May 22. Circulation. 2019. PMID: 31116032 Free PMC article. Review.
Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are of major importance, but a lack of standardization in defining this population limits trial design, data interpretation, and clinical decision-making. The Acad …
Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are of major importance …
Pregnancy and delivery in women with von Willebrand disease.
Castaman G, James PD. Castaman G, et al. Eur J Haematol. 2019 Aug;103(2):73-79. doi: 10.1111/ejh.13250. Epub 2019 May 31. Eur J Haematol. 2019. PMID: 31107984 Free PMC article. Review.
However, there are also instances during pregnancy (amniocentesis, vaginal bleeding associated with placental detachment, sudden abortion) that may require urgent hemostatic treatment to prevent bleeding. ...For these latter women, the risk of vaginal bleeding …
However, there are also instances during pregnancy (amniocentesis, vaginal bleeding associated with placental detachment, sudden abor …
Randomized Trial of Platelet-Transfusion Thresholds in Neonates.
Curley A, Stanworth SJ, Willoughby K, Fustolo-Gunnink SF, Venkatesh V, Hudson C, Deary A, Hodge R, Hopkins V, Lopez Santamaria B, Mora A, Llewelyn C, D'Amore A, Khan R, Onland W, Lopriore E, Fijnvandraat K, New H, Clarke P, Watts T; PlaNeT2 MATISSE Collaborators. Curley A, et al. N Engl J Med. 2019 Jan 17;380(3):242-251. doi: 10.1056/NEJMoa1807320. Epub 2018 Nov 2. N Engl J Med. 2019. PMID: 30387697 Clinical Trial.
METHODS: In this multicenter trial, we randomly assigned infants born at less than 34 weeks of gestation in whom severe thrombocytopenia developed to receive a platelet transfusion at platelet-count thresholds of 50,000 per cubic millimeter (high-threshold group) or 25,000 per cu …
METHODS: In this multicenter trial, we randomly assigned infants born at less than 34 weeks of gestation in whom severe thrombocytopenia dev …
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
ASCEND Study Collaborative Group; Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S, Armitage J. ASCEND Study Collaborative Group, et al. N Engl J Med. 2018 Oct 18;379(16):1529-1539. doi: 10.1056/NEJMoa1804988. Epub 2018 Aug 26. N Engl J Med. 2018. PMID: 30146931 Free article. Clinical Trial.
The primary efficacy outcome was the first serious vascular event (i.e., myocardial infarction, stroke or transient ischemic attack, or death from any vascular cause, excluding any confirmed intracranial hemorrhage). The primary safety outcome was the first major bleedi …
The primary efficacy outcome was the first serious vascular event (i.e., myocardial infarction, stroke or transient ischemic attack, or deat …
Diagnosis and treatment of von Willebrand disease in 2024 and beyond.
James P, Leebeek F, Casari C, Lillicrap D. James P, et al. Haemophilia. 2024 Apr;30 Suppl 3:103-111. doi: 10.1111/hae.14970. Epub 2024 Mar 13. Haemophilia. 2024. PMID: 38481079 Review.
This condition is almost certainly the most common inherited bleeding disorder, and the major symptomatic burden of the disease is experienced by females during their reproductive years. Diagnosis relies on the identification of a personal and family history of excessive m …
This condition is almost certainly the most common inherited bleeding disorder, and the major symptomatic burden of the disease is ex …
Patient blood management guideline for adults with critical bleeding.
Mitra B, Jorgensen M, Reade MC, Keegan A, Holley A, Farmer S, Harvey N, Winearls J, Parr M, French CJ; Clinical and Consumer Reference group for the update of Patient Blood Management Guidelines (Module 1: Critical Bleeding/Massive Transfusion). Mitra B, et al. Med J Aust. 2024 Mar 4;220(4):211-216. doi: 10.5694/mja2.52212. Epub 2024 Jan 28. Med J Aust. 2024. PMID: 38282333
INTRODUCTION: The management of patients with critical bleeding requires a multidisciplinary approach to achieve haemostasis, optimise physiology, and guide blood component use. ...In the setting of trauma and obstetric haemorrhage, administration of tranexamic acid within …
INTRODUCTION: The management of patients with critical bleeding requires a multidisciplinary approach to achieve haemostasis, optimis …
2,678 results